Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as TR-700 (active moiety)
TR-700 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Pilot study | EXPERIMENTAL | 3 subjects, open lable, microdialysis single dose. |
| Main Study | EXPERIMENTAL | 12 subjects, open label, single dose of 600 mg. |
| Name | Type | Description |
|---|---|---|
| TR-700 (active moiety) | DRUG | A TR-700 solution will be locally administered via a microdialysis probe into the skeletal muscle and subcutanous tissue (just under the skin) at a concentration of approximately 2 µg/mL at a flow rate of 1.5 µL/min for 60 minutes for a total maximum dose of 0.36 µg (0.18 µg per probe). |
| TR-701 (pro-drug) | DRUG | Each subject enrolled in the Main study will receive a single oral dose of 600mg TR-701 |
Inclusion Criteria: * Body mass index of 20 to 29 kg/m2 * Agree not to consume any products containing tobacco, alcohol, quinine, grapefruit, caffeine, or high levels of tyramine * Agree not to use any other medication * Female subjects must be postmenopausal (for at least 6 months), surgically ste...
TR-700 is an investigational small molecule developed by Merck & Company, Inc. (ticker MRK). It is in Phase 1 clinical development, and its intended therapeutic indications have not been disclosed. TR-700 is also referred to as TR-700 (active moiety).
TR-700 is being developed by Merck & Company, Inc., which trades under the ticker MRK. Merck is the sponsor behind the clinical research conducted on this investigational small molecule.
TR-700 is in Phase 1 clinical development. It is an investigational small molecule and has not been approved by the FDA. One Phase 1 trial has been completed, and no trials are currently active.
TR-700 has been studied in one completed Phase 1 trial, NCT00666601, titled Microdialysis and Pharmacokinetic Study of TR-701. That trial enrolled 15 healthy adult volunteers in the United States and used a controlled design without randomization or double blinding.
TR-700 is the active moiety of TR-701. The completed Phase 1 trial for TR-700, NCT00666601, was titled Microdialysis and Pharmacokinetic Study of TR-701, reflecting the relationship between the two names.
The therapeutic indications for TR-700 have not been disclosed. It is an investigational small molecule in Phase 1 development at Merck & Company, Inc., and its completed trial, NCT00666601, was conducted in healthy adult volunteers rather than in a patient population.